RECRUITINGOBSERVATIONAL

Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma

Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma That Aim to Achieve and Maintain Measurable Residual Disease (MRD)-Negativity in Community Oncology Settings

About This Trial

All4Cure is partnering with community oncology practices participating in the Quality Cancer Care Alliance (QCCA) and Exigent Research to develop a clinical pathway that standardizes the evaluation, treatment and ongoing management of patients with newly diagnosed multiple myeloma who wish to achieve and maintain MRD negativity. This is a longitudinal retrospective study that will collect data from three separate cohorts of patients with newly diagnosed multiple myeloma (NDMM). The cohorts classify patients based on whether care is delivered under an intention to adhere to an MRD-targeted clinical pathway, and if so, whether the implementation of that clinical pathway occurs through participation in the All4Cure platform vs. through written documentation. The three cohorts are labeled: Platform, Documentation, and Off-Pathway.

Who May Be Eligible (Plain English)

Who May Qualify: - Diagnosis of multiple myeloma - Diagnosis must occur on or after the formal launch of the MRD-targeted clinical pathway in the Exigent network - Diagnosis must be indicated by the presence of any of the following diagnostic codes for multiple myeloma: \[C90.00\] - Diagnosis must be confirmed on human review of the medical record - Age ≥ 18 years at qualifying diagnosis. - Patient has continued to receive care at a QCCA/Exigent Research practice for at least 90 days after the index date. Patients in the Documentation Cohort must meet the following additional inclusion criteria. • Evidence in the record of a threshold level of adherence to the clinical pathway, or implied intention to adhere to the clinical pathway. In addition to the inclusion criteria for the documentation cohort, patients in the Platform Cohort must meet the following additional inclusion criteria. - A record of registration by the patient for participation in the All4Cure platform, including signed HIPAA release forms that allow All4Cure to access their medical records. - A record of registration by the patient's primary treating physician for participation in the All4Cure platform. Who Should NOT Join This Trial: - Patients with a concurrent other malignancy (except basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancies of breast or cervix), or those who have received treatment of another malignancy within three years prior to diagnosis of multiple myeloma (except for treatment of basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancies of breast or cervix), are excluded from eligibility. - Patients with multiple myeloma subtypes Immunoglobulin D (IgD) or Immunoglobulin E (IgE) are excluded due to the very low rate of these subtypes. - Patients who transfer their care to another facility outside the QCCA/Exigent Research network within the first 90 days after NDMM diagnosis are excluded. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Diagnosis of multiple myeloma * Diagnosis must occur on or after the formal launch of the MRD-targeted clinical pathway in the Exigent network * Diagnosis must be indicated by the presence of any of the following diagnostic codes for multiple myeloma: \[C90.00\] * Diagnosis must be confirmed on human review of the medical record * Age ≥ 18 years at qualifying diagnosis. * Patient has continued to receive care at a QCCA/Exigent Research practice for at least 90 days after the index date. Patients in the Documentation Cohort must meet the following additional inclusion criteria. • Evidence in the record of a threshold level of adherence to the clinical pathway, or implied intention to adhere to the clinical pathway. In addition to the inclusion criteria for the documentation cohort, patients in the Platform Cohort must meet the following additional inclusion criteria. * A record of registration by the patient for participation in the All4Cure platform, including signed HIPAA release forms that allow All4Cure to access their medical records. * A record of registration by the patient's primary treating physician for participation in the All4Cure platform. Exclusion Criteria: * Patients with a concurrent other malignancy (except basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancies of breast or cervix), or those who have received treatment of another malignancy within three years prior to diagnosis of multiple myeloma (except for treatment of basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancies of breast or cervix), are excluded from eligibility. * Patients with multiple myeloma subtypes Immunoglobulin D (IgD) or Immunoglobulin E (IgE) are excluded due to the very low rate of these subtypes. * Patients who transfer their care to another facility outside the QCCA/Exigent Research network within the first 90 days after NDMM diagnosis are excluded.

Treatments Being Tested

OTHER

Multiple Myeloma Pathway

Use and adherence to a multiple myeloma pathway.

OTHER

All4Cure Platform

Participant in the All4Cure platform.

OTHER

Documentation Pathway

Use of multiple myeloma pathway through written documentation.

Locations (1)

All4Cure

Seattle, Washington, United States